

Sex Differences in the Impact of BMI on Length of Hospital Stay in Hypertensive Patients Admitted to a Cardiology Department: A Retrospective Cohort Study

Katarzyna Łokieć^{1,2}, Bartosz Uchmanowicz³, Adrian Kwaśny², Grzegorz Kubiela^{3,4}, Jacek Smereka⁵, Stanisław Surma⁶, Anthony Dissen⁷, Michał Czapla^{5,8,9}

¹Department of Propaedeutic of Civilization Diseases, Medical University of Lodz, Lodz, Poland; ²Institute of Dietetics, The Academy of Business and Health Science, Lodz, Polska; ³Department of Nursing, Faculty of Nursing and Midwifery, Wrocław Medical University, Wrocław, Poland; ⁴Department of Health Care Services, Polish National Health Fund, Central Office in Warsaw, Warsaw, Poland; ⁵Department of Emergency Medical Service, Faculty of Nursing and Midwifery, Wrocław Medical University, Wrocław, Poland; ⁶Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland; ⁷School of Health Sciences, Stockton University, Galloway, NJ, USA; ⁸Institute of Heart Diseases, University Hospital, Wrocław, Poland; ⁹Group of Research in Care (GRUPAC), Faculty of Health Sciences, University of La Rioja, Logroño, Spain

Correspondence: Michał Czapla, Department of Emergency Medical Service, Wrocław Medical University, ul. Parkowa 34, 51-616, Wrocław, Poland, Email michal.czapla@umw.edu.pl

Background and purpose: Body mass index (BMI), as a straightforward measure, is widely used in clinical practice, and its results are linked to HT and patient prognosis. This study aimed to ascertain if sex differences exist in the prognostic significance of BMI at the time of admission to the cardiology unit, and how this impacts the LOHS for patients suffering from hypertension.

Patients and methods: A retrospective analysis of the medical records of 486 patients admitted urgently with a diagnosis of HT to the Cardiology Department at University Hospital in Wrocław (Poland) between January 2017 and June 2021 was conducted.

Results: Women accounted for 53% of the study group and were older than men (64.7 ± 12.8 vs 60.5 ± 11.8 , $p=0.466$). The mean BMI in women was 28.49 ± 5.39 and in men 29.14 ± 4.88 . In an unadjusted linear regression model BMI results were not independent predictors of LOHS in either sex. After adjusting the model for comorbidities and blood test results, significant independent predictors of LOHS in women were LDL ($B=-0.02$, $p<0.001$), HDL ($B=-0.043$, $p=0.012$), TC ($B=0.015$, $p=0.007$), and hsCRP ($B=0.02$, $p=0.013$), while in men they were LDL ($B=-0.026$, $p<0.001$), HDL ($B=-0.058$, $p=0.003$), and TC ($B=0.022$, $p=0.002$).

Conclusions: The result of BMI assessed at the time of a patient's admission to the cardiology department is not a significant predictor of LOHS in both men and women with hypertension.

Keywords: hypertension, obesity, BMI, sex differences, LOHS

Introduction

Cardiovascular disease (CVD) represents a formidable challenge in public health, with hypertension (HT) standing as a predominant global health concern currently estimated to be affecting one-third of the adult population.¹ The World Health Organization underscores the criticality of this issue, noting that inadequate treatment of HT is pervasive with approximately 80% of HT patients receiving suboptimal care. Enhancing treatment coverage could potentially avert up to 76 million deaths by 2050.¹ The intricacies of hospitalization for HT patients, notably the Length of Hospital Stay (LOHS), are influenced by a confluence of factors including, but not limited to, obesity status and multimorbidity.² Furthermore, the complexity of CVD correlates with an prolonged LOHS, necessitating an astute prediction model for LOHS to optimize healthcare outcomes.³

Research and findings within the medical literature highlight BMI as a pivotal, modifiable determinant impacting patient prognosis.⁴ BMI, as a straightforward measure, is widely used in clinical practice, and its results are linked to HT

and patient prognosis. Elevated BMI may be associated with worsening blood pressure control and mortality.⁵ The simplicity and cost-effectiveness of BMI measurement make it as clinically significant as, if not more than, precise measures of total adiposity.⁶ Obesity, particularly marked by excessive visceral fat, is a known exacerbator of HT due to the resultant hormonal and inflammatory alterations impairing vascular endothelium function. Thus, weight management is fundamental in treating obesity-related metabolic sequelae.^{7,8} The relationship between BMI and all-cause mortality in patients with hypertension (HT) appears to follow a U-shaped curve.⁹ Both underweight (BMI < 18.5 kg/m²) and obesity (BMI ≥ 30 kg/m²) may prolong LOHS and worsen patient prognosis.^{10,11}

Additionally, burgeoning research on sex differences in HT has revealed disparities in disease prevalence, public awareness, and sex-specific cardiovascular risk and pathophysiology.^{12,13} Notwithstanding advancements in HT management, these sex disparities remain inadequately addressed, leading to potential suboptimal treatment outcomes, particularly for women.^{14,15} This gap highlights the exigency for in-depth exploration of sex-dependent determinants in HT's clinical trajectory. Remarkably, the nexus between BMI, sex, and LOHS in HT remains under-researched, signifying a pivotal area for future inquiry. This dearth of data justifies the imperative for comprehensive studies to elucidate these interrelations, potentially informing tailored treatment strategies in HT management. As such, the purpose of this research was to ascertain if sex differences exist in the prognostic significance of BMI at the time of admission to the cardiology unit, and how this impacts the LOHS for patients suffering from hypertension.

Materials and Methods

Study Design and Setting

The study conducted a retrospective analysis of the medical records of 486 patients who were urgently admitted with a diagnosis of arterial hypertension (ICD10: I10) to the Cardiology Department (Institute of Heart Diseases), in University Hospital in Wrocław (Poland) between January 2017 and June 2021 was conducted.

Study Population and Data

The analysis incorporated the medical records of all patients who met the following inclusion criteria: emergency admission to the Institute of Heart Diseases for HT, and those aged ≥18 years. Finally, data from 486 patients were analyzed, including the following: BMI, length of hospital stay (LOHS), HT grade, comorbidities: heart failure (HF), diabetes mellitus (DM), chronic kidney disease (CKD), a history of cerebral stroke (CS) or myocardial infarction (MI), and laboratory tests: triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), high-sensitivity C-reactive protein (hsCRP), albumin, transferrin, procalcitonin, thyroid-stimulating hormone (TSH), potassium (K), sodium (Na) and haemoglobin A1c (HbA1c). The WHO criteria were used to classify patients as obese (BMI ≥ 30 kg/m²), overweight (BMI 25–29.9 kg/m²), normal body weight (BMI 18.5–24.9 kg/m²), and underweight (BMI < 18.5 kg/m²).¹⁶ The BMI score was calculated and recorded in the patient's medical record by the physician at the time of admission to the hospital.

Ethical Considerations

The study was conducted following the principles of the Declaration of Helsinki and approved by the independent Bioethics Committee of Wrocław Medical University, protocol no. KB-837/2022. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. The Bioethics Committee determined that obtaining informed consent from patients was not required due to the retrospective design of the study, which involved the analysis of anonymized medical records.

Statistical Analysis

For comparing qualitative variables across groups, the chi-squared test was applied, incorporating Yates' correction for 2×2 tables. Where contingency tables exhibited low values, Fisher's exact test was employed as a substitute. The Mann–Whitney test facilitated comparisons of quantitative variables between two groups. To assess the influence of specific variables on continuous outcomes, linear regression analysis was conducted, presenting regression parameters along with

their 95% confidence intervals. The significance threshold for all statistical analyses was established at 0.05. Calculations were performed using R version 4.3.0.

Results

Analysis of Sex Differences

The study included a total of 586 patients hospitalized due to hypertension. Women constituted 54.8% (n = 321) of the study population, while men accounted for 45.2% (n = 265). The mean age of participants was 63.3 years (SD = 12.7), with a median age of 65 years. The mean BMI was 28.8 kg/m² (SD = 5.16), with 19.4% of patients classified as having normal weight (BMI 18.5–24.9), 31.9% as overweight (BMI 25–29.9), and 30.9% as obese (BMI ≥30). Only 1.2% of the study population was underweight (BMI < 18.5).

Hypertension grades were distributed as follows: grade 1 (20.7%), grade 2 (50.9%), and grade 3 (18.9%). The average length of hospital stay (LOHS) was 3.53 days (SD = 2.78), with obese individuals experiencing a mean hospital stay of 3.4 ± 2.43 days, and underweight individuals staying the longest at 5.14 ± 2.27 days. Detailed demographic and clinical characteristics are presented in Table 1.

For sex differences, women were significantly older than men and had significantly higher HDL, TC, TSH, and Na levels, while men had significantly higher K levels (Table 1).

Table 1 Group Characteristics: Sex Differences

Parameter		Female (N=257)	Male (N=229)	Total (N=486)	p
Length of hospital stay [days]	Mean (SD)	3.4 (2.81)	3.15 (2.47)	3.28 (2.66)	p=0.466
	Median (quartiles)	3 (1–5)	3 (1–4)	3 (1–4)	
	Range	1–21	1–19	1–21	
Age [years]	Mean (SD)	64.7 (12.84)	60.56 (11.76)	62.75 (12.5)	p<0.001*
	Median (quartiles)	67 (57–73)	62 (54–68)	64 (56–71)	
	Range	22–93	22–89	22–93	
HT grade	Grade 1	47 (18.29%)	51 (22.27%)	98 (20.16%)	p=0.465
	Grade 2	139 (54.09%)	114 (49.78%)	253 (52.06%)	
	Grade 3	47 (18.29%)	38 (16.59%)	85 (17.49%)	
	Unknown	24 (9.34%)	26 (11.35%)	50 (10.29%)	
BMI [kg/m ²]	18.5–24.9	68 (26.46%)	44 (19.21%)	112 (23.05%)	p=0.251
	<18.5	4 (1.56%)	3 (1.31%)	7 (1.44%)	
	25.0–29.9	91 (35.41%)	95 (41.48%)	186 (38.27%)	
	≥30	94 (36.58%)	87 (37.99%)	181 (37.24%)	
HF	No	220 (85.60%)	199 (86.90%)	419 (86.21%)	p=0.778
	Yes	37 (14.40%)	30 (13.10%)	67 (13.79%)	
DM	No	190 (73.93%)	158 (69.00%)	348 (71.60%)	p=0.27
	Yes	67 (26.07%)	71 (31.00%)	138 (28.40%)	
CKD	No	225 (87.55%)	194 (84.72%)	419 (86.21%)	p=0.44
	Yes	32 (12.45%)	35 (15.28%)	67 (13.79%)	
CS	No	222 (86.38%)	199 (86.90%)	421 (86.63%)	p=0.973
	Yes	35 (13.62%)	30 (13.10%)	65 (13.37%)	
MI	No	240 (93.39%)	215 (93.89%)	455 (93.62%)	p=0.968
	Yes	17 (6.61%)	14 (6.11%)	31 (6.38%)	

(Continued)

Table I (Continued).

Parameter		Female (N=257)	Male (N=229)	Total (N=486)	p
TG [mg/dl]	Mean (SD)	125.74 (58.44)	136.48 (74.5)	130.77 (66.59)	p=0.503
	Median (quartiles)	115 (88–149)	118 (83–164)	115 (87–153)	
	Range	37–390	43–447	37–447	
	Missing	10	11	21	
LDL [mg/dl]	Mean (SD)	136.72 (58.71)	126.97 (52.35)	132.18 (55.99)	p=0.085
	Median (quartiles)	135 (91–171)	124 (88.5–158.5)	131 (89–167)	
	Range	23–370	35–415	23–415	
	Missing	10	14	24	
HDL [mg/dl]	Mean (SD)	57.07 (14.27)	49.29 (12.99)	53.43 (14.21)	p<0.001*
	Median (quartiles)	56 (48–64.5)	48 (40–57)	52 (44–61)	
	Range	15–107	9–87	9–107	
	Missing	10	12	22	
TC [mg/dl]	Mean (SD)	196.77 (53.64)	185.19 (48.47)	191.33 (51.55)	p=0.017*
	Median (quartiles)	189 (159–234)	181 (150.25–214)	185.5 (153–226)	
	Range	54–341	77–415	54–415	
	Missing	11	11	22	
CRP [mg/l]	Mean (SD)	7.5 (26.45)	7.59 (23.68)	7.54 (25.17)	p=0.631
	Median (quartiles)	2.07 (1.1–4)	1.9 (1.01–4.24)	2.05 (1.06–4.16)	
	Range	0.16–321.25	0.2–254.98	0.16–321.25	
	Missing	38	37	75	
Albumin [g/dl]	Mean (SD)	3.45 (0.62)	3.64 (0.8)	3.52 (0.68)	p=0.59
	Median (quartiles)	3.5 (3.3–3.7)	3.8 (2.9–4.4)	3.55 (3.13–3.95)	
	Range	1.8–4.5	2.6–4.5	1.8–4.5	
	Missing	242	220	462	
Transferrin [g/l]	Mean (SD)	2.51 (0.53)	2.35 (0.72)	2.42 (0.64)	p=0.423
	Median (quartiles)	2.37 (2.08–3.01)	2.25 (1.93–2.54)	2.27 (2.04–2.8)	
	Range	1.77–3.43	0.93–3.84	0.93–3.84	
	Missing	244	211	455	
Procalcitonin [ng/mL]	Mean (SD)	2.43 (10.4)	1.56 (4.17)	2.02 (8.04)	p=0.225
	Median (quartiles)	0.03 (0.02–0.16)	0.08 (0.03–0.61)	0.05 (0.02–0.3)	
	Range	0.01–50.01	0.01–18.15	0.01–50.01	
	Missing	234	209	443	
TSH3 [uIU/mL]	Mean (SD)	1.69 (1.39)	1.52 (1.12)	1.61 (1.27)	p=0.023*
	Median (quartiles)	1.46 (0.96–2.06)	1.23 (0.75–1.93)	1.34 (0.86–2.04)	
	Range	0.01–15.11	0.01–7.14	0.01–15.11	
	Missing	7	11	18	
K [mmol/l]	Mean (SD)	4.2 (0.5)	4.35 (0.52)	4.27 (0.51)	p=0.002*
	Median (quartiles)	4.19 (3.93–4.42)	4.28 (4.02–4.6)	4.23 (3.97–4.49)	
	Range	3.06–7.02	3.29–7.37	3.06–7.37	
	Missing	2	3	5	
Na [mmol/l]	Mean (SD)	140.09 (2.97)	139.72 (2.68)	139.92 (2.84)	p=0.009*
	Median (quartiles)	141 (139–142)	140 (139–141)	140 (139–142)	
	Range	127–148	128–152	127–152	
	Missing	2	3	5	

(Continued)

Table 1 (Continued).

Parameter		Female (N=257)	Male (N=229)	Total (N=486)	p
HbA1c [%]	Mean (SD)	6.13 (1.04)	6.05 (0.97)	6.09 (1)	p=0.145
	Median (quartiles)	5.9 (5.6–6.2)	5.8 (5.5–6.2)	5.8 (5.5–6.2)	
	Range	4.3–10.7	4.6–10	4.3–10.7	
	Missing	84	55	139	

Notes: Quantitative variables: Mann–Whitney test; p - qualitative variables: chi-squared or Fisher's exact test. *Statistically significant ($p < 0.05$).

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CS, cerebral stroke; DM, diabetes mellitus; HF, heart failure; HDL, high-density lipoprotein; HbA1c, haemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; HT, Hypertension; K, potassium; LDL, low-density lipoprotein; LOHS, length of hospital stay; MI, myocardial infarction; NA, sodium; TC, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.

Analysis Concerning the Prevalence of Obesity

In women with obesity, there were significantly lower concentrations of CRP ($p < 0.001$) and lower TSH levels ($p = 0.016$) compared to women without obesity. HDL levels were also significantly lower in women with obesity ($p = 0.005$). In terms of comorbidities, women with obesity exhibited a lower prevalence of diabetes mellitus (DM) but a higher prevalence of Cushing's syndrome (CS) compared to their non-obese counterparts. For men, obesity was associated with significantly higher TG levels ($p = 0.002$) and lower HDL levels ($p < 0.001$). Men with obesity had a higher prevalence of DM ($p = 0.005$) and a lower prevalence of CS ($p = 0.048$) compared to men without obesity (Table 2).

Effect of BMI on Length of Hospitalization

An unadjusted linear regression analysis indicated that none of the examined variables significantly independently predicted the duration of hospital stays for both men and women, as shown in Table 3.

The subsequent model was adjusted for comorbidities, past medical conditions, and laboratory tests results. Laboratory test results were included in the multivariate model if the missing data did not exceed 20%. For women, a significant independent predictors of LOHS was LDL ($B = -0.02$, $p < 0.001$), HDL ($B = -0.043$, $p = 0.012$), TC ($B = 0.015$, $p = 0.007$) and hsCRP ($B = 0.02$, $p = 0.013$), as shown in Table 4.

For men, a multivariate linear regression model revealed that LDL ($B = -0.026$, $p < 0.001$), HDL ($B = -0.058$, $p = 0.003$), and TC ($B = 0.022$, $p = 0.002$) were significant independent predictors of the length of LOHS, as detailed in Table 5.

Discussion

The main objective of this study was to evaluate the prevalence of sex differences in the prognostic influence of BMI, recorded at admission to the cardiology department, on the LOHS in patients with HT. Contrary to our previous research, which did not segregate patients by sex, and suggested that both underweight and obesity (as defined and classified by BMI) influenced LOHS in a univariate analysis, this study, with a sex-specific focus, did not reveal any significant association between BMI score and LOHS in either women or men diagnosed with HT.⁴

There is a notable absence of literature assessing sex differences in the prognostic impact of BMI, recorded at admission to the cardiology unit, on the length of hospital stay (LOHS) in patients with hypertension. This is surprising, considering that underweight BMI has been significantly associated with an elevated risk of mortality from various causes, including hypertension.¹⁷ In contrast, studies on other cardiovascular diseases have explored sex differences in the impact of BMI on LOHS.^{2,18–20} Additionally, scientists are increasingly focusing on women, who are often under-represented in CVD research, to better understand their unique risk profiles and improve their clinical outcomes.^{21,22}

We have shown that BMI was not associated with the length of hospital stay in either women or men with arterial hypertension. From a clinical point of view, this is very important, because arterial hypertension is the most common cardiovascular risk factor, occurring in over 29% of the adult population.^{23,24} Moreover, a large percentage of people with arterial hypertension are characterized by abnormal body weight (excess body weight is one of the most important risk factors for arterial hypertension).²⁵ This means that a large proportion of patients urgent hospitalized in cardiology

Table 2 Group Characteristics: Obesity Status (BMI ≥ 30 Kg/m²)

Parameter	Group	Female			Male		
		Non-Obese (N=163)	Obese (N=94)	p	Non-Obese (N=142)	Obese (N=87)	p
LOHS [days]	Mean (SD) Median (quartiles) Range	3.31 (2.84) 3 (1–5) 1–21	3.56 (2.76) 3 (1–5) 1–15	0.308	3.1 (2.72) 3 (1–4) 1–19	3.23 (2) 3 (1–4.5) 1–9	0.161
Age [years]	Mean (SD) Median (quartiles) Range	64.57 (14.04) 67 (58–73) 24–93	64.94 (10.53) 65 (57–72) 22–85	0.484	61.51 (12.5) 62 (55–70) 22–89	59.01 (10.31) 61 (52–66) 30–82	0.167
HT grade	Grade 1 Grade 2 Grade 3 Unknown	32 (19.63%) 85 (52.15%) 27 (16.56%) 19 (11.66%)	15 (15.96%) 54 (57.45%) 20 (21.28%) 5 (5.32%)	0.552	34 (23.94%) 69 (48.59%) 21 (14.79%) 18 (12.68%)	17 (19.54%) 45 (51.72%) 17 (19.54%) 8 (9.20%)	0.542
HF	No Yes	143 (87.73%) 20 (12.27%)	77 (81.91%) 17 (18.09%)	0.274	123 (86.62%) 19 (13.38%)	76 (87.36%) 11 (12.64%)	1
DM	No Yes	122 (74.85%) 41 (25.15%)	68 (72.34%) 26 (27.66%)	0.769	108 (76.06%) 34 (23.94%)	50 (57.47%) 37 (42.53%)	0.005*
CKD	No Yes	138 (84.66%) 25 (15.34%)	87 (92.55%) 7 (7.45%)	0.099	116 (81.69%) 26 (18.31%)	78 (89.66%) 9 (10.34%)	0.151
CS	No Yes	142 (87.12%) 21 (12.88%)	80 (85.11%) 14 (14.89%)	0.792	118 (83.10%) 24 (16.90%)	81 (93.10%) 6 (6.90%)	0.048*
MI	No Yes	151 (92.64%) 12 (7.36%)	89 (94.68%) 5 (5.32%)	0.708	133 (93.66%) 9 (6.34%)	82 (94.25%) 5 (5.75%)	1
TG [mg/dl]	Mean (SD) Median (quartiles) Range Missing	119.96 (57.36) 110 (81–144.75) 37–390 5	136 (59.23) 122 (101–155) 47–384 5	0.01*	122.8 (61.94) 106 (77–143) 43–447 5	159.63 (87.57) 133 (94–207) 50–433 6	0.002*
LDL [mg/dl]	Mean (SD) Median (quartiles) Range Missing	136.76 (64.3) 134 (86–175) 23–370 5	136.64 (47.53) 137 (100–166) 56–268 5	0.585	128.47 (46.46) 133 (90–162) 42–272 7	124.42 (61.25) 113 (84.25–144.75) 35–415 7	0.175
HDL [mg/dl]	Mean (SD) Median (quartiles) Range Missing	59.03 (15.68) 58 (48–68.75) 15–107 5	53.6 (10.56) 53 (48–59) 31–87 5	0.005*	51.38 (12.93) 50 (42–59) 9–87 6	45.78 (12.41) 45 (36–52) 23–84 6	<0.001*

TC [mg/dl]	Mean (SD) Median (quartiles) Range Missing	197.61 (56.46) 194 (157–233.75) 54–341 5	195.26 (48.45) 184.5 (164.75–234.25) 77–316 6	0.894	188.26 (48.75) 178 (155–218) 77–370 5	180 (47.84) 183 (145–207) 84–415 6	0.245
CRP [mg/l]	Mean (SD) Median (quartiles) Range Missing	8.42 (32.47) 1.92 (0.86–3.37) 0.16–321.25 25	5.92 (9.86) 3.16 (1.59–5.61) 0.37–65.84 13	<0.001*	8.12 (29.11) 1.69 (0.9–3.71) 0.2–254.98 29	6.83 (12.49) 2.36 (1.2–6.4) 0.35–80.97 8	0.067
Albumen [g/dl]	Mean (SD) Median (quartiles) Range Missing	3.46 (0.71) 3.5 (3.3–3.8) 1.8–4.5 152	3.42 (0.36) 3.55 (3.35–3.62) 2.9–3.7 90	0.844	3.33 (0.78) 3.05 (2.75–3.95) 2.6–4.4 136	4.27 (0.4) 4.5 (4.15–4.5) 3.8–4.5 84	0.092
Transferrin [g/l]	Mean (SD) Median (quartiles) Range Missing	2.55 (0.49) 2.37 (2.18–3.01) 2.02–3.43 154	2.42 (0.69) 2.37 (1.88–2.92) 1.77–3.17 90	0.604	2.24 (0.7) 2.18 (1.99–2.54) 0.93–3.84 130	2.58 (0.79) 2.31 (1.97–3.26) 1.86–3.57 81	0.574
Procalcitonin [ng/mL]	Mean (SD) Median (quartiles) Range Missing	3.6 (12.86) 0.03 (0.02–0.16) 0.01–50.01 148	0.22 (0.42) 0.04 (0.03–0.13) 0.02–1.21 86	0.625	2.69 (5.92) 0.34 (0.07–1.14) 0.02–18.15 133	0.64 (1.71) 0.06 (0.02–0.12) 0.01–5.75 76	0.109
TSH [uIU/mL]	Mean (SD) Median (quartiles) Range Missing	1.76 (1.14) 1.57 (1–2.2) 0.01–7.66 5	1.58 (1.74) 1.33 (0.89–1.89) 0.11–15.11 2	0.016*	1.54 (1.11) 1.22 (0.73–2.02) 0.07–6.07 8	1.48 (1.15) 1.23 (0.86–1.68) 0.01–7.14 3	0.972
K [mmol/l]	Mean (SD) Median (quartiles) Range Missing	4.18 (0.5) 4.18 (3.9–4.47) 3.06–7.02 1	4.23 (0.49) 4.2 (3.97–4.41) 3.34–6.84 1	0.587	4.41 (0.57) 4.3 (4.04–4.68) 3.52–7.37 2	4.25 (0.41) 4.26 (3.99–4.46) 3.29–5.78 1	0.083
Na [mmol/l]	Mean (SD) Median (quartiles) Range Missing	139.9 (3.26) 140 (138.25–142) 127–148 1	140.42 (2.38) 141 (139–142) 133–145 1	0.362	139.75 (2.88) 140 (138–141) 128–152 2	139.68 (2.34) 140 (139–141) 131–146 1	0.965
HbA1c [%]	Mean (SD) Median (quartiles) Range Missing	6.1 (1.01) 5.9 (5.5–6.2) 4.9–10.2 58	6.18 (1.09) 5.9 (5.68–6.3) 4.3–10.7 26	0.287	5.92 (0.84) 5.7 (5.5–6.1) 4.6–9.6 37	6.24 (1.12) 5.9 (5.5–6.5) 4.7–10 18	0.092

Notes: *Statistically significant ($p < 0.05$) χ^2 - Qualitative variables: chi-squared or Fisher's exact test. Quantitative variables: Mann-Whitney test.

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CS, cerebral stroke; DM, diabetes mellitus; HF, heart failure; HDL, high-density lipoprotein; HbA1c, haemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; HT, Hypertension; K, potassium; LDL, low-density lipoprotein; LOHS, length of hospital stay; MI, myocardial infarction; NA, sodium; TC, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.

Table 3 Impact of BMI on Length of Hospitalization Unadjusted Model

Model 1- Unadjusted								
Trait			N	LOHS (Mean±SD)	B	95% CI		p
Female	BMI [kg/m ²]	18.5–24.9	68	2.90±2.39	Ref.			
		<18.5	4	5.00±2.71	2.103	−0.725	4.931	0.146
		25.0–29.9	91	3.55±3.12	0.652	−0.229	1.534	0.148
		≥30	94	3.56±2.76	0.667	−0.208	1.542	0.137
Male	BMI [kg/m ²]	18.5–24.9	44	3.00±3.13	Ref.			
		<18.5	3	5.33±2.08	2.333	−0.559	5.226	0.115
		25.0–29.9	95	3.07±2.53	0.074	−0.81	0.958	0.87
		≥30	87	3.23±2.00	0.23	−0.667	1.127	0.616

Note: p - statistically significant (p<0.05).

Abbreviation: BMI, body mass index.

Table 4 Multivariate Linear Regression Model – Female

Trait		Parameter	95% CI		p
BMI [kg/m ²]	18.5–24.9	ref.			
	<18.5	1.646	−2.236	5.528	0.407
	25.0–29.9	0.586	−0.393	1.564	0.242
	≥30	0.225	−0.74	1.189	0.649
Age	[years]	0.021	−0.009	0.051	0.169
HT grade	Grade 1	ref.			
	Grade 2	−0.201	−1.22	0.818	0.699
	Grade 3	0.826	−0.431	2.084	0.2
HF	No	ref.			
	Yes	1.121	−0.148	2.39	0.085
DM	No	ref.			
	Yes	0.704	−0.193	1.602	0.126
CKD	No	Ref.			
	Yes	1.287	−0.092	2.665	0.069
Stroke	No	Ref.			
	Yes	0.247	−0.807	1.302	0.647
MI	No	Ref.			
	Yes	0.94	−0.719	2.6	0.268
TG	[mg/dl]	−0.003	−0.01	0.004	0.434

(Continued)

Table 4 (Continued).

Trait		Parameter	95% CI		p
LDL	[mg/dl]	−0.02	−0.029	−0.012	<0.001*
HDL	[mg/dl]	−0.043	−0.076	−0.01	0.012*
TC	[mg/dl]	0.016	0.004	0.027	0.007*
CRP	[mg/l]	0.02	0.004	0.036	0.013*
TSH3	[uIU/mL]	−0.131	−0.399	0.138	0.341
K	[mmol/l]	0.191	−0.637	1.019	0.652
Na	[mmol/l]	−0.111	−0.246	0.024	0.109

Note: p - multiple linear regression *Statistically significant (p<0.05).

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CS, cerebral stroke; DM, diabetes mellitus; HF, heart failure; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; HT, Hypertension; LDL, low-density lipoprotein; MI, myocardial infarction; NA, sodium; TC, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.

Table 5 Multivariate Linear Regression Model – Male

Trait		Parameter	95% CI		p
BMI [kg/m ²]	18.5–24.9	Ref.			
	<18.5	0.96	−3.633	5.552	0.683
	25.0–29.9	−0.465	−1.592	0.662	0.42
	≥30	−0.507	−1.674	0.661	0.396
Age	[years]	−0.012	−0.052	0.027	0.539
HT grade	Grade 1	Ref.			
	Grade 2	−0.893	−1.883	0.096	0.079
	Grade 3	−0.447	−1.713	0.82	0.49
HF	No	Ref.			
	Yes	−0.093	−1.348	1.161	0.885
DM	No	Ref.			
	Yes	0.201	−0.671	1.072	0.653
CKD	No	Ref.			
	Yes	−0.094	−1.435	1.248	0.891
Stroke	No	Ref.			
	Yes	−0.264	−1.573	1.046	0.694
MI	No	Ref.			
	Yes	1.127	−0.637	2.89	0.213
TG	[mg/dl]	−0.004	−0.011	0.003	0.277
LDL	[mg/dl]	−0.026	−0.036	−0.016	<0.001*

(Continued)

Table 5 (Continued).

Trait		Parameter	95% CI		p
HDL	[mg/dl]	−0.058	−0.096	−0.02	0.003*
TC	[mg/dl]	0.022	0.009	0.035	0.002*
CRP	[mg/l]	0.008	−0.018	0.034	0.553
TSH3	[ulU/mL]	0.173	−0.182	0.527	0.341
K	[mmol/l]	0.081	−0.889	1.051	0.87
Na	[mmol/l]	0.086	−0.071	0.243	0.284

Note: p - multiple linear regression *Statistically significant ($p < 0.05$).

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CS, cerebral stroke; DM, diabetes mellitus; HF, heart failure; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; HT, Hypertension; LDL, low-density lipoprotein; MI, myocardial infarction; NA, sodium; TC, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.

departments will most likely suffer from arterial hypertension and overweight/obesity. In such patients, it is worth knowing the factors indicating a greater likelihood of longer hospitalization. Some studies have shown that higher body weight was associated with better prognosis and shorter hospitalization time (eg in patients hospitalized due to exacerbation of HF).²⁶ This is the so-called “obesity paradox”, or rather, as more detailed analyses have shown - The “BMI paradox”. In our previous study, we showed that extending the analysis of the effect of BMI on the prognosis of patients with heart failure with reduced ejection fraction (HFrEF) to include a history of stroke eliminated the “BMI paradox”.²⁷ BMI, although commonly used to diagnose obesity, is a parameter that poorly reflects the actual content of adipose tissue. In a meta-analysis of 32 studies conducted by Sommer et al, it was found that the use of BMI to diagnose obesity (defined by the percentage of fat mass) was characterized by low sensitivity (detection of the disease in a priori sick population) 51.4% (95% CI: 38.5–64.2) and good specificity (exclusion of the disease in a priori healthy individuals) 95.4% (95% CI: 90.7–97.8) in women and 49.6% (95% CI: 34.8–64.5) and 97.3% (95% CI: 92.1–99.1) in men.²⁸ Therefore, the exclusive use of BMI in the diagnosis of obesity may result in its under-identification. BMI does not always have explanatory power for assessing body weight, as it does not consider the percentage distribution of fat (not reflect the distribution of visceral adipose tissue) and non-fat body mass in the total body weight. Moreover, BMI does not assess the mass or strength of skeletal muscles. These parameters are extremely important in the context of assessing the prognosis of patients.²⁷ Moreover, the “obesity paradox” is observed in more physically active individuals with better glycemic control.^{29–31} Analysis of the relationship between BMI and prognosis, extended to include treatment, region, age, gender, systolic blood pressure, heart rate, renal function, left ventricular ejection fraction, BMI, NYHA functional class, HF etiology, HF duration, previous hospitalization due to HF, history of diabetes, atrial fibrillation and NT-proBNP eliminates the “obesity paradox”. The use of the waist-to-hip ratio (WHR) correlates better with the prognosis of patients.³² We have shown that the predictors of longer hospitalization were parameters related to lipid profile and inflammation markers (in each sex were LDL, HDL, TC, and in women specifically, hsCRP levels). It is worth emphasizing that BMI does not fully correlate with the LDL level.³³ Obesity does not always coexist with metabolic disorders, which is why we distinguish between metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Moreover, we can also distinguish between metabolically unhealthy normal body weight (MUNW). Both MUO and MUNW are characterized by a higher cardiovascular risk and a worse prognosis.³⁴ It is worth remembering that obese patients with arterial hypertension are characterized by a higher risk of poor blood pressure control, which may also contribute to a worse prognosis.³⁵ Based solely on BMI measurement, it is impossible to distinguish whether the patient has MHO or MUO, and even less so MUNW. From the clinical point of view and cardiovascular risk, it is not the average BMI (usually measured on admission to the hospital) that is important, but the long-term BMI variability. It has been shown that higher BMI variability was a significant risk marker associated with

adverse cardiovascular events independent of mean BMI across major racial and ethnic groups.³⁶ Very interesting results were provided by the study by Yoshida et al, which found that the influence of BMI on prognosis depended on the specific cardiovascular disease (among which acute HF, acute myocardial infarction, acute aortic dissection, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage were at higher risk in patients with AHF or IS. Age was a significant factor influencing prognosis independently of BMI.³⁷ A factor that may have a significant impact on prognosis in patients with arterial hypertension, regardless of BMI and gender, is its duration. It was shown that longer arterial hypertension duration was associated with increased cardiovascular risk and overall death in a linear fashion, and these associations were independent of blood pressure control levels.³⁸ Blood pressure variability during hospitalization also significantly affects the prognosis of patients and may contribute to prolonging the duration of hospital stay.³⁹ Elevated hsCRP levels indicate the presence of low-grade inflammation, which contributes to the occurrence of many diseases, not only cardiovascular diseases and may also affect the general condition of hospitalized patients with arterial hypertension.⁴⁰ While some laboratory results in our study such as LDL, HDL, TC, and hsCRP were significant predictors of LOHS in the multivariate analysis, all these values were within normal ranges, indicating that their clinical relevance may be limited despite statistical significance. Therefore, the results of our study indicate that the prediction of the length of hospitalization in patients with hypertension should be approached holistically and many factors should be taken into account and interpreted as a whole (and not individual parameters, and especially not only BMI).

Study Limitation

Due to the study's retrospective design, patients' body composition was not examined using methods such as electrical bioimpedance, and no anthropometric measurements were taken. The study was based solely on BMI results and did not assess the patients' actual body composition. It should be noted that sex differences in anthropometric measurements could potentially affect prognosis, representing a limitation of the study. Laboratory tests were not standardized (each time the doctor decided to perform tests), resulting in differences between patients. The lack of standardized testing could have introduced variability and bias into the results. Additionally, the manuscript does not account for the medications used by the patients, which could significantly impact the length of hospitalization and study outcomes, particularly with regard to lipid parameters and CRP levels. The omission of this critical information may introduce bias and limit the interpretation of the findings, as the effects of various drugs on these parameters are well-documented. Furthermore, the assessment of the long-term survival of HT patients was limited due to legal restrictions on access to patient data under Polish law. Another limitation of this study is its single-center design, as the data were derived from patients admitted to one cardiology department. This may restrict the generalizability of our findings to other healthcare settings or populations with different characteristics. However, the hospital serves a diverse patient population from urban and rural areas, which partially supports the representativeness of the sample. Nonetheless, future multicenter studies are needed to validate and expand upon our results.

Conclusions

Underweight (BMI < 18.5 kg/m²), overweight (BMI 18.5–24.9 kg/m²), and obesity (BMI ≥ 30 kg/m²), as assessed by body mass index at the time of admission to the cardiology department, were not significant independent predictors of length of hospitalization in either men or women with hypertension. Further prospective studies are necessary to investigate factors related to sex differences and nutritional status, including the utilization of alternative nutritional status indicators beyond BMI, and their impact on the length of hospitalization in this group of patients.

Disclosure

The authors report no conflicts of interest in this work.

References

1. First WHO report details devastating impact of hypertension and ways to stop it. Available from: <https://www.who.int/news/item/19-09-2023-first-who-report-details-devastating-impact-of-hypertension-and-ways-to-stop-it>. Accessed October 25, 2023.

2. Tsai PFJ, Chen PC, Chen YY, et al. Length of hospital stay prediction at the admission stage for cardiology patients using artificial neural network. *J Healthc Eng*. 2016;2016:7035463. doi:10.1155/2016/7035463
3. Daghistani TA, Elshaw R, Sakr S, Ahmed AM, Al-Thwayee A, Al-Mallah MH. Predictors of in-hospital length of stay among cardiac patients: a machine learning approach. *Int J Cardiol*. 2019;288:140–147. doi:10.1016/j.ijcard.2019.01.046
4. Czapla M, Juárez-Vela R, Lokieć K, Wleklík M, Karniej P, Smereka J. The association between nutritional status and length of hospital stay among patients with hypertension. *Int J Environ Res Public Health*. 2022;19(10):5827. doi:10.3390/ijerph19105827
5. Landi F, Calvani R, Picca A, et al. Body mass index is strongly associated with hypertension: results from the longevity check-up 7+ study. *Nutrients*. 2018;10(12):1976. doi:10.3390/nu10121976
6. Ortega FB, Sui X, Lavie CJ, Blair SN. Body mass index, the most widely used but also widely criticized index: would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality? *Mayo Clin Proc*. 2016;91(4):443–455. doi:10.1016/j.mayocp.2016.01.008
7. Seravalle G, Grassi G. Obesity and hypertension. *Pharmacol Res*. 2017;122:1–7. doi:10.1016/j.phrs.2017.05.013
8. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. *Gland Surg*. 2020;9(1):80–93. doi:10.21037/gs.2019.12.03
9. Xu W, Shubina M, Goldberg SI, Turchin A. Body mass index and all-cause mortality in patients with hypertension. *Obesity*. 2015;23(8):1712–1720. doi:10.1002/oby.21129
10. Zizza C, Herring AH, Stevens J, Popkin BM. Length of hospital stays among obese individuals. *Am J Public Health*. 2004;94(9):1587–1591. doi:10.2105/AJPH.94.9.1587
11. Kim HJ, Kim BS, Lee JH, Shin JH. Impact of underweight on 3-year all-cause mortality in patients with acute severe hypertension: a retrospective cohort study. *Sci Rep*. 2022;12:4798. doi:10.1038/s41598-022-08892-9
12. Cífková R, Strilchuk L. Sex differences in hypertension. do we need a sex-specific guideline? *Front Cardiovasc Med*. 2022;9. doi:10.3389/fcvm.2022.960336
13. Kałużna-Oleksy M, Krysztofiak H, Sawczak F, et al. Sex differences in the nutritional status and its association with long-term prognosis in patients with heart failure with reduced ejection fraction: a prospective cohort study. *Eur J Cardiovasc Nurs*. 2024;zvad105. doi:10.1093/eurjcn/zvad105
14. Francis-Morel G, Guevara NA, Malik M, Sotello D. Gender disparities in hypertensive emergency admissions: a national retrospective cohort study. *Cureus*. 2023;15(6):e40287. doi:10.7759/cureus.40287
15. Regensteiner JG, Reusch JEB. Sex differences in cardiovascular consequences of hypertension, obesity, and diabetes. *J Am Coll Cardiol*. 2022;79(15):1492–1505. doi:10.1016/j.jacc.2022.02.010
16. World Health Organization Consultation on Obesity 1999. Available from: <https://apps.who.int/iris/handle/10665/42330>. Accessed December 31, 2022.
17. Zhou Q, Liu X, Zhao Y, et al. BMI and risk of all-cause mortality in normotensive and hypertensive adults: the rural Chinese cohort study. *Public Health Nutr*. 2021;24(17):5805–5814. doi:10.1017/S1368980021001592
18. Kanic V, Suran D. Sex differences in the relationship between body mass index and outcome in myocardial infarction. *Am J Med Sci*. 2023;366(3):219–226. doi:10.1016/j.amjms.2023.04.020
19. Forhan M, Qiu W, Terada T, et al. Female sex is associated with extended length of hospital stay following CABG surgery in patients with severe obesity. *Can J Cardiol*. 2016;32(4):S5. doi:10.1016/j.cjca.2016.02.017
20. Kwaśny A, Lokieć K, Uchmanowicz B, Młynarska A, Smereka J, Czapla M. Sex-related differences in the impact of nutritional status on length of hospital stay in atrial fibrillation: a retrospective cohort study. *Front Public Health*. 2023;11:1223111. doi:10.3389/fpubh.2023.1223111
21. Tobb K, Kocher M, Bullock-Palmer RP. Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling. *Am Heart J Plus Cardiol Res Pract*. 2022;13:100109. doi:10.1016/j.ahjo.2022.100109
22. Bosomworth J, Khan Z. Analysis of gender-based inequality in cardiovascular health: an umbrella review. *Cureus*. 2023;15(8):e43482. doi:10.7759/cureus.43482
23. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010
24. López-Bueno R, Núñez-Cortés R, Calatayud J, et al. Global prevalence of cardiovascular risk factors based on the life's essential 8 score: an overview of systematic reviews and meta-analysis. *Cardiovasc Res*. 2024;120(1):13–33. doi:10.1093/cvr/cvad176
25. Qiao W, Zhang X, Kan B, et al. Hypertension, BMI, and cardiovascular and cerebrovascular diseases. *Open Med Wars Pol*. 2021;16(1):149–155. doi:10.1515/med-2021-0014
26. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. *JACC Heart Fail*. 2013;1(2):93–102. doi:10.1016/j.jchf.2013.01.006
27. Czapla M, Surma S, Kwaśny A, Lewandowski L. Association of body mass index with outcomes in patients with Heart Failure with Reduced Ejection Fraction (HFREF). *Nutrients*. 2024;16(15):2473. doi:10.3390/nu16152473
28. Sommer I, Teufer B, Szegal M, et al. The performance of anthropometric tools to determine obesity: a systematic review and meta-analysis. *Sci Rep*. 2020;10(1):12699. doi:10.1038/s41598-020-69498-7
29. Fröhlich H, Bossmeyer A, Kazmi S, et al. Glycaemic control and insulin therapy are significant confounders of the obesity paradox in patients with heart failure and diabetes mellitus. *Clin Res Cardiol*. 2024;113(6):822–830. doi:10.1007/s00392-023-02268-3
30. Quesada O, Lauzon M, Buttle R, et al. Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women? *Eur J Prev Cardiol*. 2022;29(12):1608–1614. doi:10.1093/eurjpc/zwac046
31. McAuley PA, Artero EG, Sui X, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. *Mayo Clin Proc*. 2012;87(5):443–451. doi:10.1016/j.mayocp.2012.01.013
32. Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. *Eur Heart J*. 2023;44(13):1136–1153. doi:10.1093/eurheartj/ehad083
33. Shamaï L, Lux E, Shen M, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. *Obes Surg*. 2011;21(1):42–47. doi:10.1007/s11695-010-0170-7
34. Preda A, Carbone F, Tirandi A, Montecucco F, Liberale L. Obesity phenotypes and cardiovascular risk: from pathophysiology to clinical management. *Rev Endocr Metab Disord*. 2023;24(5):901–919. doi:10.1007/s11154-023-09813-5

35. Hammami R, Bahloul A, Triki S, et al. Impact of overweight and obesity on blood pressure control among hypertensive patients (results from nature HTN). *J Hypertens*. 2021;39(39):e339. doi:10.1097/01.hjh.0000748444.35042.87
36. Almuwaqqat Z, Hui Q, Liu C, et al. Long-term body mass index variability and adverse cardiovascular outcomes. *JAMA Netw Open*. 2024;7(3):e243062. doi:10.1001/jamanetworkopen.2024.3062
37. Nakane C, Yokote T, Nishimura T, Furukawa S, Inoue S. Association between active hobby before hospitalization and frailty at discharge in patients with acute cardiovascular disease. *Prog Rehabil Med*. 2024;9:20240007. doi:10.2490/prm.20240007
38. Zheng Y, Gao X, Jia HY, Li FR, Ye H. Influence of hypertension duration and blood pressure levels on cardiovascular disease and all-cause mortality: a large prospective cohort study. *Front Cardiovasc Med*. 2022;9:948707. doi:10.3389/fcvm.2022.948707
39. Lazzaroni D, Castiglioni P, Camaiera U, et al. In hospital day-by-day blood pressure variability: a marker of adverse outcome in secondary cardiovascular prevention. *J Hypertens*. 2019;37(37):e79. doi:10.1097/01.hjh.0000571152.45483.43
40. Surma S, Sahebkar A, Nutrition BM. Nutraceuticals and bioactive compounds in the prevention and fight against inflammation. *Nutrients*. 2023;15(11):2629. doi:10.3390/nu15112629

Vascular Health and Risk Management

Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/vascular-health-and-risk-management-journal>